Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report

• Main Authors: Ryo Takada (Author), Miki Fujiwara (Author), Masatoshi Maki (Author), Naoyuki Nomura (Author), Shintaro Kono (Author), Akira Fujita (Author), Hiroshi Masumoto (Author), Yoko Takahashi (Author), Yasuhisa Hasegawa (Author), Koji Tamura (Author)
• Format: Book
• Published: BMC, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi + Nivo therapy. The primary tumor was cured by surgery, and a patholog...